

Ref. No: 1062
Date: 08/07/24
Subject: Diffuse Large B Cell Lymphoma

REQUEST

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)**
- **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**
- **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)**
- **Axicabtagene ciloleucel (Yescarta)**
- **Tisagenlecleucel**
- **Epcoritamab**
- **Loncastuximab tesirine**
- **Glofitamab**
- **Any other SACT**

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- **Axicabtagene ciloleucel (Yescarta)**
- **Tisagenlecleucel**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatments**

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatment**

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Patients diagnosed 01.12.23 – 31.05.24 with Diffuse Large B Cell Lymphoma (DLBCL)

St Helens and Knowsley sites	Southport and Ormskirk sites
15	<5

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

St Helens and Knowsley	Southport and Ormskirk
14	<5

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

	St Helens and Knowsley	Southport and Ormskirk
R-CHOP	7	<5
Pola-BR	0	0
Pola-R-CHP	<5	<5
Pola-R-CHP+Ras	<5	0

This is based on primary treatments only.

The trust only had records of patients receiving the regimens mentioned so no records of patients receiving the others.

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- **Axicabtagene ciloleucel (Yescarta)**
- **Tisagenlecleucel**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatments**

This information is not held

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

St Helens and Knowsley	Southport and Ormskirk
<5	<5

5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

This information is not held.

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.